Do Eliquis (apixaban) and clopidogrel affect the activated partial thromboplastin time (aPTT)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Effect of Eliquis (Apixaban) and Clopidogrel on aPTT

Apixaban causes minimal, clinically insignificant prolongation of aPTT that is not useful for monitoring, while clopidogrel has no direct effect on aPTT.

Apixaban's Effect on aPTT

Apixaban does prolong aPTT, but the effect is small, highly variable, and not clinically useful for monitoring anticoagulation 1. The FDA label explicitly states that "changes observed in these clotting tests at the expected therapeutic dose, however, are small, subject to a high degree of variability, and not useful in monitoring the anticoagulation effect of apixaban" 1.

Key Evidence on Apixaban and aPTT:

  • Minimal prolongation: At therapeutic doses, apixaban causes only modest aPTT prolongation. Even at supratherapeutic concentrations (225 ng/mL), aPTT was prolonged only 1.15-fold compared to baseline 2

  • Dose-dependent but limited: In single-dose studies, a 50 mg dose (far exceeding therapeutic levels) increased aPTT by only 1.2-fold from baseline 3

  • Not reagent-sensitive: Unlike PT testing where reagent choice matters significantly, aPTT reagents show no appreciable difference in sensitivity to apixaban 2

  • European guidelines confirm: The 2018 EHRA guidelines note that apixaban has limited impact on aPTT compared to other anticoagulants, with the symbol "(↑)" indicating minimal effect 4

Clinical Implications:

Do not use aPTT to monitor apixaban therapy. If you need to assess apixaban levels:

  • Use calibrated anti-Factor Xa chromogenic assays for quantitative measurement 4
  • A normal aPTT does NOT exclude therapeutic apixaban levels 4
  • aPTT cannot reliably guide clinical decisions about apixaban dosing or reversal

Clopidogrel's Effect on aPTT

Clopidogrel does not affect aPTT. Clopidogrel is an antiplatelet agent that inhibits the P2Y12 receptor on platelets—it has no direct effect on the coagulation cascade measured by aPTT. The FDA label for apixaban confirms "no pharmacodynamic interactions were observed with aspirin, clopidogrel, or prasugrel" 1.

Combined Use Considerations

When apixaban and clopidogrel are used together:

  • Bleeding risk increases due to combined antiplatelet and anticoagulant effects 1
  • aPTT remains unreliable for monitoring either drug
  • The combination showed enhanced antithrombotic effects in microfluidic studies but with dose-dependent bleeding risk 5

Important Caveat:

If you're checking aPTT in a patient on both drugs and considering heparin bridging, be aware that apixaban will interfere with aPTT-based heparin monitoring. In this scenario, use anti-Xa activity to monitor heparin instead 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.